Is pyoderma gangrenosum associated with solid malignancies? Insights from a population-based cohort study

被引:4
作者
Kridin, Khalaf [1 ,2 ]
Britva, Rimma Laufer [3 ]
Bitan, Dana Tzur [4 ]
Damiani, Giovanni [5 ,6 ]
Cohen, Arnon D. [7 ,8 ]
机构
[1] Univ Lubeck, Lubeck Inst Expt Dermatol, Ratzeburger Allee 160, D-23562 Lubeck, Germany
[2] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel
[3] Israel Inst Technol, Haifa, Israel
[4] Ariel Univ, Dept Behav Sci, Ariel, Israel
[5] IRCCS Ist Ortoped Galeazzi, Clin Dermatol, Milan, Italy
[6] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy
[7] Clalit Hlth Serv, Tel Aviv, Israel
[8] Ben Gurion Univ Negev, Fac Hlth Sci, Siaal Res Ctr Family Med & Primary Care, Beer Sheva, Israel
关键词
case-control study; cohort study; Pyoderma gangrenosum; solid malignancies; DISEASES;
D O I
10.1111/ajd.13631
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The question of whether solid malignancies (SMs) are associated with pyoderma gangrenosum (PG) remains to be conclusively answered. Objective: To evaluate the risk of SM among patients with PG and the odds of PG after a diagnosis of SM. Methods: A population-based retrospective cohort study was conducted to study the risk for SM in patients with PG (n = 302) as compared with age-, sex- and ethnicity-matched control subjects (n = 1799). A case-control design was used to estimate the odds of PG in those with a preexisting history of SM. Results: The prevalence of a preexisting SM was comparable in patients with PG and controls (7.5% vs. 8.8%, respectively; P = 0.490). The odds of having PG following a diagnosis of a SM was not statistically increased (OR, 0.85; 95% CI, 0.53-1.36). The incidence of SM was 6.8 (95% CI, 3.5-12.2) and 7.9 (95% CI, 6.1-10.1) per 1000 person-years among patients with PG and controls, respectively. Patients with PG were not more likely to develop SM as compared to controls (HR, 0.86; 95% CI, 0.44-1.69). Patients with a dual diagnosis of PG and SM were older and had more frequent comorbid conditions and increased mortality. Conclusions: SM is not associated with provoking PG, and patients with PG are not at an increased risk of developing SM. A thorough routine screening for SM in patients with new-onset PG is an unnecessary approach based on the study findings.
引用
收藏
页码:336 / 341
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 2018, JAMA DERMATOL
[2]   Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients [J].
Binus, A. M. ;
Qureshi, A. A. ;
Li, V. W. ;
Winterfield, L. S. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) :1244-1250
[3]   Pathophysiology of pyoderma gangrenosum (PG): An updated review [J].
Braswell, Sara F. ;
Kostopoulos, Tassia C. ;
Ortega-Loayza, Alex G. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (04) :691-698
[4]   Inpatient Management of Pyoderma Gangrenosum Treatments, Outcomes, and Clinical Implications [J].
Cabalag, Miguel Suhady ;
Wasiak, Jason ;
Lim, Shueh Wen ;
Raiola, Frank Bruscino .
ANNALS OF PLASTIC SURGERY, 2015, 74 (03) :354-360
[5]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[6]  
GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439
[7]   Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease [J].
Gupta, Angela S. ;
Ortega-Loayza, Alex G. .
ANNALS OF HEMATOLOGY, 2019, 98 (09) :2247-2248
[8]  
Hasselmann Dirk O, 2007, J Dtsch Dermatol Ges, V5, P560, DOI 10.1111/j.1610-0387.2007.0328.x
[9]   Quantification of the relationship between pyoderma gangrenosum and Crohn's disease: a population-based case-control study [J].
Kridin, Khalaf ;
Damiani, Giovanni ;
Ludwig, Ralf J. ;
Tzur-Bitan, Dana ;
Cohen, Arnon D. .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (07) :814-818
[10]   Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study [J].
Kridin, Khalaf ;
Damiani, Giovanni ;
Cohen, Arnon D. .
CLINICAL RHEUMATOLOGY, 2021, 40 (02) :521-528